Clinical Trials

New Search
Title   Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety
Disease/Condition   Thyroid Cancer
Eligibility Criteria   Ages Eligible for Study: 18 Years and older (Adult, Senior) Genders Eligible for Study: Both Accepts Healthy Volunteers: No Click here for eligibility requirements
Principal Investigator   Missak Haigentz, MD
Contact Name   Karen Fehn
Phone   (718) 405-8446
Contact Email   CPDMUtrialinfo@montefiore.org
IRB/Protocol Number   IRB# 15-06-381-01
Status   Enrolling
Adult Clinical Trial   Yes
Pediatric Clinical Trial   No